Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.
Also called NCT02683746
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 308 participants
- Sponsor
- Registry
-
NCT02683746
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02683746. Randomized; double masking; primary purpose treatment. Start 2016-03-16 (actual); primary completion 2017-04-03 (actual). Results posted on 2018-05-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Lyophilized albiglutide DCC pen injector
- Intervention (Drug)
- Lyophilized albiglutide DCC pen injector matching placebo
- Intervention (Drug)
- Albiglutide liquid auto-injector
- Intervention (Drug)
- Albiglutide liquid auto-injector matching placebo
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct02683746- Content hash
4c97823d524bb307fdc1a3ed77a912400a4acd2a7f50b73c70be9f7c2616fe0a